IM Cannabis Corp Achieves Profit Growth Amid Revenue Challenges in Q2 2025

IM Cannabis Corp ( (IMCC) ) has issued an update.

IM Cannabis Corp reported a 14% decrease in revenue for Q2 2025 compared to the previous year, primarily due to challenges such as the ongoing war in Israel and supply chain delays. Despite these challenges, the company achieved a significant increase in gross profit and margin, reflecting strong cost management and operational efficiency. The company’s strategic focus on profitability and margin growth has positioned it well for future sustainable growth, despite the current revenue setbacks.

The most recent analyst rating on (IMCC) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on IM Cannabis Corp stock, see the IMCC Stock Forecast page.

Spark’s Take on IMCC Stock

According to Spark, TipRanks’ AI Analyst, IMCC is a Neutral.

IM Cannabis Corp’s overall stock score is primarily impacted by its financial struggles, including ongoing losses and negative cash flows. Despite these challenges, recent earnings call highlights significant improvements in the German market and successful cost-cutting measures, which contribute positively to the score. The technical analysis indicates a bearish trend, and the valuation remains unattractive due to negative earnings. The absence of notable corporate events further emphasizes the need for strategic improvements to enhance the company’s financial health.

To see Spark’s full report on IMCC stock, click here.

More about IM Cannabis Corp

IM Cannabis Corp is an international medical cannabis company operating primarily in the medical cannabis industry. The company focuses on providing cannabis products and services in markets such as Israel and Germany.

Average Trading Volume: 274,985

Technical Sentiment Signal: Hold

Current Market Cap: $9.04M

Find detailed analytics on IMCC stock on TipRanks’ Stock Analysis page.